Last reviewed · How we verify
LYN-057
At a glance
| Generic name | LYN-057 |
|---|---|
| Also known as | LYN-057 (50 mg) |
| Sponsor | Lyndra Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LYN-057 CI brief — competitive landscape report
- LYN-057 updates RSS · CI watch RSS
- Lyndra Inc. portfolio CI